Posted in Market Access Beyond GLP-1Rs: emerging targets poised to gain share of obesity market April 20, 2026 Pharmaceutical Technology Non-GLP-1 obesity drugs are emerging in the market, with this landscape expected to surge 50-fold, generating $15.5bn in 2031. Market AccessMetabolic & GLP-1Read full story